Clinical trials sponsored by Regeneron Pharmaceuticals

Phase breakdown

Conditions studied

Recruiting trials led by Regeneron Pharmaceuticals

• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
  NCT06413680 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
  NCT07543055 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 2 locations
• A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
  NCT07527910 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
  NCT05519475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 71 locations
• A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
  NCT07220772 · Phase: Phase 3 · Ages: 2 Years and older · Sex: All (male and female) · 1 location
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 111 locations
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
  NCT04077099 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 40 locations
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07154290 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 34 locations
• A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
  NCT05125016 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 14 locations
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  NCT03972657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  NCT05648214 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
  NCT05106387 · Phase: Not specified · Ages: 18 Years to 70 Years · Sex: All (male and female) · 9 locations
• An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
  NCT03936335 · Phase: Not specified · Ages: 18 Years to 49 Years · Sex: Female · 1 location
• An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
  NCT05363319 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
  NCT06975787 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 18 locations
• First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
  NCT06351592 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 22 locations
• First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
  NCT07216066 · Phase: Phase 1 · Ages: 50 Years to 80 Years · Sex: All (male and female) · 2 locations
• First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
  NCT07527923 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
  NCT07594106 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
  NCT07594093 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
  NCT07175428 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 81 locations
• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
  NCT07626411 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 32 locations
• Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
  NCT07430956 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
  NCT06585410 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
  NCT07685808 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
  NCT07318597 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
  NCT07271186 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 58 locations
• Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
  NCT07493304 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations

Common questions

How many trials is Regeneron Pharmaceuticals recruiting for?

Regeneron Pharmaceuticals is the lead sponsor of 29 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.